TEVA PHARMA, S.L.U - αποτελεσματα

Ευρωπαϊκή Ένωση - Νορβηγικά - EMA (European Medicines Agency)

dasatinib accordpharma

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Νορβηγία - Νορβηγικά - Statens legemiddelverk

fingolimod teva 0.5 mg

teva gmbh - fingolimodhydroklorid - kapsel, hard - 0.5 mg

Ευρωπαϊκή Ένωση - Νορβηγικά - EMA (European Medicines Agency)

clopidogrel acino pharma

acino pharma gmbh - klopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel er angitt i voksne for forebygging av atherothrombotic hendelser i:pasienter som lider av hjerteinfarkt (fra noen få dager til mindre enn 35 dager), ischaemic slag (fra 7 dager til mindre enn 6 måneder) eller etablert perifer arteriell sykdom. for ytterligere informasjon, vennligst referer til seksjon 5.

Ευρωπαϊκή Ένωση - Νορβηγικά - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrelhydroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antithrombotic agents - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Νορβηγία - Νορβηγικά - Statens legemiddelverk

calciumfolinate teva 10 mg/ ml

teva sweden ab - kalsiumfolinat - injeksjonsvæske, oppløsning - 10 mg/ ml

Νορβηγία - Νορβηγικά - Statens legemiddelverk

metformin karo pharma 1000 mg

karo pharma as - metforminhydroklorid - tablett, filmdrasjert - 1000 mg

Νορβηγία - Νορβηγικά - Statens legemiddelverk

metformin karo pharma 500 mg

karo pharma as - metforminhydroklorid - tablett, filmdrasjert - 500 mg

Νορβηγία - Νορβηγικά - Statens legemiddelverk

metformin karo pharma 850 mg

karo pharma as - metforminhydroklorid - tablett, filmdrasjert - 850 mg